| # | Filing Date | Period End Date | Type | Report Link | 
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
																	Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA (cfDNA) and precision medicine, today announced it will expand its...
																	
																	
																	BTIG analyst Mark Massaro maintains Natera (NASDAQ:NTRA) with a Buy and raises the price target from $200 to $210.
																	Data to be featured in Presidential Symposium at ESMOSignatera™ changes the paradigm by expanding the adjuvant decision window,...
																	Canaccord Genuity analyst Kyle Mikson maintains Natera (NASDAQ:NTRA) with a Buy and maintains $200 price target.